drugset / Trial / NCT01174914
Effectiveness Study Low-Dose Naltrexone Versus ARV's for HIV+
RandomizedParallel-groupSingle-blindPrevention
Summary
In the vast majority of those infected with HIV virus who are untreated, there is deterioration in immune health over a period of months or years inevitably leading to full-blown AIDS and demise. Treatment with ARV's stop or slow down this deterioration if started before a certain degree of progression occurs and has saved millions of lives. The investigators' study hypothesis is that effectiveness of a very low dose of an FDA-approved medication, naltrexone hydrochloride, (Low-Dose Naltrexone, or LDN) will compare favorably to ARV's to prevent progression of HIV+ toward immune deterioration and full-blown AIDS.
Timeline
- Start
- 2008-03
- Primary completion
- 2010-03
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Naltrexone | Small molecule | 3 mg | Oral |
| Comparator | Azidothimidine | Unknown | — | — |
| Comparator | Efavirenz | Other / unclassified | — | — |
| Comparator | Lamivudine | Other / unclassified | — | — |
| Comparator | Lopinavir | Other / unclassified | — | — |
| Comparator | Nevirapine | Small molecule | — | — |
| Comparator | Stavudine | Other / unclassified | — | — |
| Comparator | Tenofovir | Small molecule | — | — |
| Comparator | emtricitabine | Other / unclassified | — | — |
Indications
No indication recorded.